Eculizumab
- Generic Name
- Eculizumab
- Brand Names
- Soliris, Epysqli, Bekemv
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 219685-50-4
- Unique Ingredient Identifier
- A3ULP0F556
- Background
Eculizumab is a monoclonal antibody that targets complement protein C5. Binding to this protein prevents the activation of a complement terminal complex, which is used to treat a number of autoimmune conditions.
...
- Indication
Eculizumab is indicated in the US to treat paroxysmal nocturnal hemoglobinuria (PNH) to reduce hemolysis, atypical hemolytic uremic syndrome to inhibit complement-mediated thrombotic microangiopathy, and neuromyelitis optica spectrum disorder (NMOSD). It is also indicated in EU to treat PNH in both adult and pediatric patients.
- Associated Conditions
- Generalized Myasthenia Gravis, Neuromyelitis Optica Spectrum Disorders, Paroxysmal Nocturnal Haemoglobinuria (PNH), Thrombotic Microangiopathies
- Associated Therapies
- -
Efficacy, Safety, PK, PD, and ADA of Eculizumab in Chinese Adults With NMOSD
- Conditions
- Interventions
- First Posted Date
- 2024-12-09
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 21
- Registration Number
- NCT06724809
- Locations
- 🇨🇳
Research Site, Wuhan, China
Complement C5 mAb in the Treatment of Anti-GBM Disease
- First Posted Date
- 2024-07-22
- Last Posted Date
- 2024-08-05
- Lead Sponsor
- Peking University First Hospital
- Target Recruit Count
- 8
- Registration Number
- NCT06513338
- Locations
- 🇨🇳
Peking University First Hospital, Beijing, China
Eculizumab for Prevention of Antibody-Mediated Rejection in ABO-Incompatible Living Donor Kidney Transplantation
- First Posted Date
- 2024-06-11
- Last Posted Date
- 2024-06-13
- Lead Sponsor
- Tao Lin
- Target Recruit Count
- 30
- Registration Number
- NCT06453135
- Locations
- 🇨🇳
West China Hospital, Sichuan University, Chengdu, Sichuan, China
Eculizumab in Adult Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) in China
- Conditions
- Interventions
- First Posted Date
- 2023-06-02
- Last Posted Date
- 2024-11-05
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 25
- Registration Number
- NCT05886244
- Locations
- 🇨🇳
Research Site, Wuhan, China
Eculizumab in Pediatric and Adult Participants With Atypical Hemolytic Uremic Syndrome (aHUS) in China
- First Posted Date
- 2023-05-25
- Last Posted Date
- 2024-11-07
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 25
- Registration Number
- NCT05876351
- Locations
- 🇨🇳
Research Site, Wuhan, China
A Study to Evaluate How Safe Pozelimab + Cemdisiran Combination Therapy is and How Well it Works in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Who Have Not Recently Received or Have Not Received Complement Inhibitor Treatment
- Conditions
- Interventions
- First Posted Date
- 2021-11-24
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 190
- Registration Number
- NCT05133531
- Locations
- 🇵🇪
Clinica San Felipe, Lima, Peru
🇵🇭St Lukes Medical Center, Quezon City, Central Luzon, Philippines
🇨🇳Taichung Veterans General Hospital (VGHTC), Taichung City, Taiwan
Efficacy and Safety of the Combination of Pozelimab and Cemdisiran Versus Continued Eculizumab or Ravulizumab Treatment in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria
- Conditions
- Interventions
- First Posted Date
- 2021-11-23
- Last Posted Date
- 2023-08-16
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 2
- Registration Number
- NCT05131204
- Locations
- 🇺🇸
Regeneron Research Facility, Whittier, California, United States
BCX9930 for Treatment of PNH in Subjects With Inadequate Response to C5 Inhibitor Therapy
- Conditions
- Interventions
- First Posted Date
- 2021-11-11
- Last Posted Date
- 2024-02-23
- Lead Sponsor
- BioCryst Pharmaceuticals
- Target Recruit Count
- 12
- Registration Number
- NCT05116774
- Locations
- 🇬🇧
Investigative Site, London, United Kingdom
Renal Function in Highly Sensitized Patients 1 Year After Desensitization With Imlifidase Prior to DD Kidney Tx
- Conditions
- Interventions
- First Posted Date
- 2021-06-22
- Last Posted Date
- 2024-11-21
- Lead Sponsor
- Hansa Biopharma AB
- Target Recruit Count
- 64
- Registration Number
- NCT04935177
- Locations
- 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States
🇺🇸Georgetown Transplant Institute, Washington, District of Columbia, United States
🇺🇸Columbia University, New York, New York, United States
Complement Regulation to Undo Systemic Harm in Preeclampsia
- Conditions
- Interventions
- First Posted Date
- 2021-01-27
- Last Posted Date
- 2023-11-29
- Lead Sponsor
- Cedars-Sinai Medical Center
- Target Recruit Count
- 2
- Registration Number
- NCT04725812
- Locations
- 🇺🇸
Cedars-Sinai Medical Center, Los Angeles, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.